0918 GMT - Roche posted a solid first quarter, exceeding sales expectations and reaffirming its annual guidance despite the Trump administration tariff concerns, Barclays analysts say in a note. The Swiss pharma company's blockbuster drugs for multiple sclerosis Ocrevus and eye treatment Vabysmo missed Barclays' and market consensus, the analysts say. Investors will focus on diagnostics sales, hampered by pricing reforms in China, and Vabysmo's sales performance, which could slow down in the U.S. due to potential Medicare funding issues, they say. Shares fall 0.4% to 257.10 Swiss francs. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
April 24, 2025 05:18 ET (09:18 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。